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Abstract
Background: Clostridium difficile (CD)‐associated colitis (CDAC) is endemic and a common nosocomial enteric
disease encountered by surgeons in modern hospitals due to prophylactic or therapeutic antibiotic therapies.
Currently, the incidence of fulminant CDAC, which readily causes septic shock followed by multiple organ
dysfunction syndromes, is increasing. Fulminant CDAC requires surgeons to perform a prompt surgery, such as
subtotal colectomy, to remove the septic source. It is known that fulminant CDAC is caused by the shift from an
inflammatory response at a local mucosal level to a general systemic inflammatory reaction in which CD
toxin-induced mediators’ cascades disseminate. Recently, it has been proven that polymyxin B hemoperfusion
(PMX-HP) improves septic shock and recombinant human thrombomodulin (rhTM) controls disseminated
intravascular coagulation (DIC). In addition, clinically and basically, it has been shown that these treatments can
control serous chemical mediators. Therefore, it is considered that these treatments are promising ones for patients
with fulminant CDAC. In the current report, we present that these treatments without surgery contributed to the
improvement of sepsis due to fulminant CDAC.
Case presentation: We encountered a case who developed fulminant CDAC with septic shock and DIC after
laparoscopic gastrectomy for gastric cancer. At admission to the intensive care unit, his APACHE II score was 22,
which indicated an estimated risk of hospital death of 42.4 %. Our therapies were not the subtotal colectomy to
remove septic sources but the combination treatments with both PMX-HP and rhTM. These combination therapies
resulted in excellent outcomes, namely the dramatic improvement of septic shock and DIC and the patient’s
survival. We speculate that these combination therapies completely inhibit the CD toxin-induced mediators’
cascades and correspond to the removal of septic sources.
Conclusions: We recommend both PMX-HP and rhTM for patients who develop fulminant CDAC with septic shock
and DIC to increase the survival benefit and replace the need for surgical treatment.
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Background
Clostridium difficile (CD)-associated colitis (CDAC),
which is one of the common nosocomial enteric diseases
encountered by surgeons, is typically due to the expos-
ure of antibiotics and consequently endemic disease in
modern hospitals [1–3]. Recently, the incidence of ful-
minant CDAC, which readily causes septic shock
followed by multiple organ dysfunction syndromes
(MODS), is increasing [4–7]. Fulminant CDAC often re-
quires surgeons to perform a prompt invasive surgical
treatment, such as a subtotal colectomy, in order to re-
move the septic source and improve the patient’s fatal
situation [7–19].
Recently, it has been proven that polymyxin B hemo-
perfusion (PMX-HP) improves septic shock [20–23] and
recombinant human thrombomodulin (rhTM) controls
disseminated intravascular coagulation (DIC) [24–29]. In
addition, clinically and basically it has been shown that
these treatments can control serous chemical mediators.
On the other hand, it is known that fulminant CDAC
with MODS is caused by the shift from an inflammatory
response at a local mucosal level to a general systemic
inflammatory reaction in which CD toxin-induced medi-
ators’ cascades disseminate [30–36]. Therefore, it is con-
sidered that these treatments are promising ones for
patients with fulminant CDAC.
In the current report, we present that these treatments
without surgery contributed to the improvement of sep-
sis due to fulminant CDAC.
Case presentation
A 51-year-old male patient who underwent laparoscopic
partial gastrectomy for early gastric cancer had been given
intravenous cefazolin for 2 days preventively and 5 days
after the surgery suddenly developed a high-grade fever
(over 39 °C) and severe diarrhea. We immediately admin-
istered oral vancomycin (VCM), Lac-B, viz. probiotics;
and enough extracellular fluid because we empirically sus-
pected that these symptoms were due to CDAC or
methicillin-resistant Staphylococcus aureus-associated en-
teritis. A diagnosis of CDAC was rapidly made by con-
firming the presence of toxin A in his feces. Although
these medications were initiated, 24 h after the onset the
patient developed septic shock requiring vasopressor
agents and MODS composed of DIC and acute renal fail-
ure (ARF). When he was transferred to the intensive care
unit (ICU), his Acute Physiology and Chronic Health
Evaluation (APACHE) II score [37] was 22, which esti-
mated his risk of hospital death to be 42.4 % (Table 1). Ac-
cording to the clinical and radiological findings, he did
not have any colonic perforation or toxic megacolon; thus,
we avoided an invasive surgery (such as subtotal colec-
tomy) but alternatively treated him using both PMX-HP
to improve septic shock [20–23] and rhTM to control
DIC [24–29]. In the first 6 h after starting both treat-
ments, his systolic blood pressure (SBP) improved, re-
quirement for the vasopressor agent decreased, and body
temperature (BT) dropped by approximately two degrees.
Twenty-four hours after the treatments, septic shock was
dramatically improved (Fig. 1). Three days after the treat-
ments, an improvement in severe inflammation was noted
according to white blood cell (WBC) count and C-reactive
protein (CRP) level (Fig. 2) and an improvement in DIC
according to the fibrin degradation product (FDP) level
and prothrombin time (PT) (Fig. 3). A temporary decline
in the platelet count was controllable with platelet transfu-
sion (Fig. 3). Although four cycles of continuous hemodia-
filtration (CHDF) were necessary as a replacement
therapy to ARF, the further progression of MODS was not
Table 1 Vital signs, APACHE II score, and laboratory data at the
time of ICU transfer
Body temperature (°C) 40 Ht (%) 43.8
Symbolic blood pressure (mmHg) 80 WBC (/μl) 18500
Median blood pressure (mmHg) 43 PLT (×104/μl) 14.8
Administration of dopamin (γ) 10 T. bil (mg/dl) 3.4
Heart rate (/min) 150 Na (mEq/l) 137
Respiratory rate (/min) 32 K (mEq/l) 4.4
Urine output (ml/h) 5 Scr (mg/dl) 5.21
Glasgow coma scale 15 CRP (mg/dl) 24.2
APACHE II score 22 PT (%) 55
Estimated risk of hospital death (%) 42.4 FDP (μg/ml) 36.5
pH 7.38
PaO2/FiO2 (mmHg) 322
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, Ht
hematocrit, WBC white blood cell, PLT platelet, T. bil total bilirubin, Na serum
sodium, K serum potassium, Scr serum creatinine, CRP C-reactive protein, PT
prothrombin time, FDP fibrin degradation products, pH hydrogen ion
concentration, PaO2 airway opening pressure, FiO2 fraction of inspired oxygen
Fig. 1 Clinical course of the vital signs and treatments.
Abbreviations: SBP systolic blood pressure, BT body temperature,
DOP dopamine, PMX-HP polymyxin B hemoperfusion, rhTM
recombinant human thrombomodulin
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observed and the APACHE II score satisfactorily de-
creased daily (Fig. 4). Although clinically moderate
diarrhea and a mild fever were observed, his general
condition also improved. Consecutive toxin A tests,
except the first one, were all negative. Five days after
the treatments, the patient overcame fulminant CDAC
through the use of the abovementioned therapies.
Throughout the entire clinical course, neither endo-
toxemia nor bacteremia was observed.
Discussion
Currently, CDAC is endemic and a common nosocomial
enteric disease encountered by surgeons in modern hos-
pitals due to prophylactic or therapeutic antibiotic ther-
apies [1–3]. Recently, both the incidence and the
severity of CDAC have been increasing, and one possible
explanation for these increases is the emergence of
highly toxigenic and lethal strains of CD [4–7]. The
above shows the need for surgeons to consider more ser-
ious treatment against CDAC. In fulminant CDAC,
which has a higher lethal rate, it is especially necessary
for surgeons to promptly decide whether or not to per-
form an invasive surgical treatment, such as subtotal col-
ectomy, which means the removal of the septic sources
and probable improvement of the patients’ ill condition
[7–19].
In our case that suddenly developed fulminant CDAC
with septic shock requiring vasopressor agents and
MODS composed of DIC and ARF, prompt surgical
treatment in order to remove the septic sources was rec-
ommended. However, we alternatively treated the patient
with both PMX-HP and rhTM therapies. The reason for
having chosen these treatments is as follows: (1) there
was neither colonic perforation nor toxic megacolon,
which absolutely requires surgery; (2) PMX-HP is an ef-
fective extracorporeal blood purification treatment for
improving septic shock [22]; and (3) rhTM can effect-
ively inhibit systemic dissemination of intravascular co-
agulation [24–29]. The combination therapies produced
excellent outcomes in this case, namely the dramatic im-
provement of septic shock and DIC, the inhibition of
MODS progression, and the patient’s survival. We
speculate that the two below-mentioned factors corre-
sponded to the removal of the septic source, namely as
result of the surgical treatment. First, oral VCM medica-
tion could suppress CD’s proliferation and the further
production of CD toxins. Second, both PMX-HP and
rhTM could completely inhibit the CD toxin-induced
mediators’ cascades. This notion is based on the follow-
ing evidence. First, fulminant CDAC with MODS is
caused by the shift from an inflammatory response at a
Fig. 2 Clinical course of the WBC count, serum CRP level, and
treatments. Abbreviations: WBC white blood cell, CRP C-reactive
protein, PMX-HP polymyxin B hemoperfusion, rhTM recombinant
human thrombomodulin
Fig. 3 Clinical course of the PLT count, blood FDP level, blood PT
level, and treatments. Abbreviations: PLT platelet, FDP fibrin
degradation product, PT prothrombin time, PMX-HP polymyxin B
hemoperfusion, rhTM recombinant human thrombomodulin
Fig. 4 Clinical course of the APACHE II score and treatments.
Abbreviations: PMX-HP polymyxin B hemoperfusion, rhTM
recombinant human thrombomodulin, APACHE II Acute Physiology
and Chronic Health Evaluation II
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local mucosal level to a general systemic inflammatory
reaction in which CD toxin-induced mediators’ cascades
disseminate [30–36]. Second, although PMX-HP
removes circulating endotoxin by adsorption and theor-
etically prevents the progression of the biological cas-
cade of sepsis, several studies and published reports
have demonstrated that PMX-HP can reduce the plasma
levels of cytokines and sepsis-related factors, namely
TNF-α, IL-6, IL-10, N-arachidonoylethanolamine (AEA),
2-arachidonoyl glycerol (2-AG), and high-mobility group
box-1 (HMGB-1) [21, 23, 38, 39]. Indeed, there were
case reports published which showed that PMX-HP de-
creases the serum levels of endogenous cannabinoids
(anandamide and 2-AG) and inflammatory cytokine (IL-
6) in parallel with the clinical improvement of fulminant
CDAC [40, 41]. Third, many studies and fundamental
researches have shown that rhTM also has an anti-
inflammatory ability through both the activated protein
C and the lectin-like domain-dependent pathway [42–
46]. In particular, the thrombin-rhTM complex demon-
strates an anti-inflammatory ability through neutralizing
HMGB-1 [47, 48], which is known to be a mediator of
lethality and is released from necrotic cells or macro-
phages/activated dendritic cells with potent pro-
inflammatory function, which in turn causes shock or
MODS when being disseminated in the systemic circula-
tion [49–51]. Finally, septic shock and MODS in our
case were not induced by endotoxemia or bacteremia,
and a dramatic improvement was observed immediately
after the initiation of the combination therapies.
Conclusions
Both PMX-HP and rhTM therapies for patients who de-
velop fulminant CDAC with septic shock and DIC can
provide survival benefits and replace the need for inva-
sive surgical treatments to remove the septic sources.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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